Strategy
Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.
Even though the ink has long dried on the US-South Korea trade deal, new threats have prompted Celltrion to reiterate its “fundamental solution” to tariff concerns.
Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Sun Pharma’s generic Wegovy product has cleared regulatory review, positioning the company to enter India’s obesity drug market once patent protection lapses.
ANI’s Cortrophin Gel is benefiting from significant under-penetration in areas such as nephrology, neurology, rheumatology and pulmonology, the firm told attendees to the recent J.P. Morgan Healthcare Conference.
As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Hikma has launched its Enoby and Xtrenbo denosumab biosimilars to Amgen’s Prolia and Xgeva into the competitive US market. How will the firm fare against so many other rivals?
Biocon Biologics has become one of the most prominent global biosimilars firms since its buyout of former partner Viatris’ biosimilars business. With a rumored IPO instead making way for a merger with generics unit Biocon Ltd, the business’s chief Shreehas Tambe sets out the reasons for the move.
A joint pilot between Phlow and AI biotech Enveda suggests high-quality data and deep learning could cut Phlow’s active pharmaceutical ingredient development from years to months.
Sun terms reports of acquisitive interest in Organon as "speculative," at least for now. Bankers see a potential transaction fit the profile of a 'typical’ Sun deal, which if it occurs also catapults the Indian firm’s foray into biosimilars.
With needed funds in its pocket, Biocon is prepared to simplify and integrate its growing off-patent medicines portfolio under one roof.
Samsung Bioepis has significantly expanded its biosimilars pipeline with the addition of six new candidates. Management provided full details at the J.P. Morgan Healthcare conference.
European CNS specialist rolls out a value-added methylphenidate and a first-to-market guanfacine generic as it sharpens its European ADHD strategy.
Amneal sees vertical integration of its biosimilars business, as well as global partnerships, as a key advantage to remain at the top of the game ahead of upcoming competition.
After years of restructuring and remediation, Viatris says its base business has stabilized and it now expects cost savings, new launches and business development to drive renewed growth beginning in 2026.
Bio Usawa continues to expand access to its Formycon/Bioeq-partnered ranibizumab biosimilar, landing its second approval in Africa.
Sandoz says the next ten years will provide a “golden decade” of off-patent competition from which it is uniquely placed to benefit – despite a relative lack of fresh loss-of-exclusivity opportunities in 2026 and 2027.